Cargando…
Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy
The development of novel chimeric antigen receptor (CAR) cell therapies is rapidly growing, with 299 new agents being reported and 109 new clinical trials initiated so far this year. One critical lesson from approved CD19-specific CAR therapies is that target isoform switching has been shown to caus...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327123/ https://www.ncbi.nlm.nih.gov/pubmed/35919495 http://dx.doi.org/10.1093/immadv/ltac009 |